Animal models of tardive dyskinesia: their use in the search for new treatment methods.
D000367:Age Factors; D000661:Amphetamine / Q000008:administration & dosage; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001058:Apomorphine / Q000008:administration & dosage; D002230:Carbidopa / Q000627:therapeutic use; D003342:Corpus Striatum / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004338:Drug Combinations / Q000627:therapeutic use; D004347:Drug Interactions; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D006168:Guinea Pigs; D006220:Haloperidol / Q000494:pharmacology; D000882:Haplorhini; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008094:Lithium / Q000008:administration & dosage; D008297:Male; D010276:Parasympatholytics / Q000008:administration & dosage; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects
D014150:Antipsychotic Agents; D004338:Drug Combinations; D010276:Parasympatholytics; D011954:Receptors, Dopamine; C009265:carbidopa, levodopa drug combination; D007980:Levodopa; D008094:Lithium; D000661:Amphetamine; D006220:Haloperidol; D002230:Carbidopa; D001058:Apomorphine; D004298:Dopamine